GSK’s latest acquisition adds next-gen pulmonary hypertension candidate, with early signs that it could influence metabolic health and aging.
In a deal that quietly carries outsized implications, global healthcare company GSK has completed its $950 million acquisition of 35Pharma Inc, a Montreal-based clinical-stage biotech focused on protein-based therapies.
It’s a $950m move with more than one target and a straightforward pipeline expansion. At its core is HS235, a drug candidate for pulmonary hypertension (PH), a life-shortening condition marked by high blood pressure in the lungs [1]. Look a little closer, this acquisition begins to look like a bet on how chronic conditions intersect as we age.
Because PH isn’t just a lung problem. It’s a systemic one. It strains the heart, disrupts oxygen flow and often overlaps with metabolic issues like obesity and insulin resistance. Around 82 million people worldwide live with some form of it, yet treatment options remain limited, and survival rates remain sobering.
If you ask clinicians what makes PH so difficult to treat, the answer is often about trade-offs. Existing drugs can help open up blood vessels in the lungs, easing pressure and improving symptoms. However, they can also pose risks – bleeding, fluid around the heart or changes in blood composition – that complicate long-term management. In some cases, treating one problem creates another.
HS235 is designed to navigate around those compromises. Instead of broadly interacting with multiple biological signals, it takes a more targeted approach, focusing on the activin receptor signaling pathway, a mechanism already proven to play a role in PH. Think of it like adjusting a single dial rather than flipping every switch in the control room. The aim is precision: keep what works, avoid what doesn’t.
By being more selective, HS235 could potentially lower the risk of side effects that limit current therapies. In chronic diseases, where patients take medications for years, that kind of refinement can make the difference between a treatment that’s theoretically effective and one that people can actually live with.
An unexpected metabolic angle
In early clinical observations, HS235 has shown signs of influencing metabolic health. Patients experienced fat-selective weight loss, preserved lean muscle mass and improved insulin sensitivity. These are not trivial outcomes; they map onto some of the most persistent challenges in aging populations.
Obesity, muscle loss and insulin resistance don’t just coexist with diseases like PH; they often accelerate them, so a therapy that addresses both vascular health and metabolism can be a multi-system intervention.
Of course, it’s early. These findings need to be confirmed in larger trials, but the signal is there, suggesting a broader shift in how drugs are designed to reshape the biological environment that allows that condition to thrive.
The financial logic behind the acquisition is clear. The global market for pulmonary hypertension therapies is projected to reach $18 billion by 2032, with newer approaches such as activin signaling inhibitors expected to take a significant share.
HS235 will sit within GSK’s Respiratory, Immunology & Inflammation (RI&I) pipeline, an area increasingly focused on the underlying drivers of chronic disease, such as inflammation and fibrosis, that cut across organs and conditions.
“HS235 is an important addition to our RI&I pipeline, which continues to expand across inflammatory and fibrotic drivers underlying multiple chronic diseases,” Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology & Inflammation, and Head of Translational & Development Sciences at GSK, told Morningstar [2].
“With approximately 82 million patients currently living with PH in its various forms, [a] high burden of morbidity associated with the disease and poor associated prognosis, with low five-year survival rates, we are committed to advancing this novel, differentiated option to expand the limited treatments currently available.”
Where this could lead
Proof-of-concept trials are expected to begin soon in two forms of the disease: pulmonary arterial hypertension (PAH) and PH linked to heart failure with preserved ejection fraction (PH-HFpEF). Both sit at the crossroads of cardiovascular decline and aging – that’s what makes this acquisition worth watching.
While it enters the pipeline as a pulmonary drug, its potential reach extends beyond the lungs. If HS235 can deliver on both safety and metabolic benefits, it could reinforce a growing idea in longevity science: that the most valuable therapies won’t target diseases in isolation, but the shared pathways that connect them.
In other words, the future of treating chronic illness may look like a network approach, where improving one system lifts others with it.
For GSK, the $950 million price tag secures a promising asset. For the field, it raises a bigger question: what happens when drugs designed for one disease start quietly improving the biology of aging itself? That’s where this story moves into something closer to transformation.
Photograph courtesy of GSK
[1] https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-35pharma-inc/
[2] https://global.morningstar.com/en-gb/news/alliance-news/1776245632291968600/gsk-completes-purchase-of-canadas-35pharma-for-usd950-million
